


<b>PTO TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing) JUN 04 2007 PATENT & TRADEMARK OFFICE	Application Number	10/686,786
	Filing Date	October 17, 2003
	First Named Inventor	P.U. Sarma, et al.
	Art Unit	1637
	Examiner Name	Angela Marie Bertagna
Total Number of Pages in This Submission	Attorney Docket Number	041144.007.1

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input checked="" type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm	Smith, Gambrell & Russell		
Signature			
Printed Name	Frederick F. Calvetti		
Date	June 4, 2007	Reg. No.	28,557

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Confirmation No.: 1769**

**Applicants** : P. U. Sarma, et al.  
**Serial No.** : 10/686,786  
**Filed** : October 17, 2003  
**Examiner** : Angela Marie Bertagna  
**Group Art Unit** : 1637  
**For** : **A METHOD OF DETECTION OF SP-A2 GENE VARIANTS  
USEFUL FOR PREDICTION OF PREDISPOSITION TO  
ASPERGILLOSIS**

**THIRD AFFIDAVIT/DECLARATION**

We, Kambadur Muralidhar and Ashok Shah, declare and state as follows:

First, we are familiar with the publication, "Association of Polymorphisms in the Collagen Region of SP-A2 with Increased Levels of Total IgE Antibodies and Eosinophilia in Patients with Allergic Bronchopulmonary Aspergillosis", J ALLERGY CLIN IMMUNOL May 2003; Vol. 111, No. 5, pp. 1001-1007;


Second, we are listed as contributing to this publication;

Third, we are associated with the Assignee of the above-identified application,

Fourth, that this publication originated with or were obtained from Shweta Saxena, Taruna Madan, and/or Puranam Usha Sarma;

Fifth, that we are familiar with United States Patent Application No(s). 10/102,731, filed March 22, 2002 and 10/686,786, filed October 17, 2003;

Sixth, that we are not inventors of the above identified subject matter;



WHEREFORE, I declare that all statements made herein of my own knowledge are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Date: May 11<sup>th</sup>, 2007

Date: May 14<sup>th</sup>, 2007

Kambadur Muralidhar  
Kambadur Muralidhar

Ashok Shah  
Ashok Shah